Citius Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Citius Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q2 2024.
  • Citius Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 13.4 %, a 15.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 13.4 +1.77 +15.2% Jun 30, 2024
Q1 2024 13.4 +2.55 +23.6% Mar 31, 2024
Q4 2023 13.4 +3.91 +41.3% Dec 31, 2023
Q3 2023 12.5 +2.97 +31.3% Sep 30, 2023
Q2 2023 11.7 +2.95 +33.8% Jun 30, 2023
Q1 2023 10.8 +2.67 +32.8% Mar 31, 2023
Q4 2022 9.48 +1.6 +20.3% Dec 31, 2022
Q3 2022 9.49 Sep 30, 2022
Q2 2022 8.72 Jun 30, 2022
Q1 2022 8.13 Mar 31, 2022
Q4 2021 7.88 Dec 31, 2021
Q3 2020 25.7 Sep 30, 2020
Q2 2020 26.8 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.